Hot on the heels of Novo Nordisk and Eli Lilly, Sanofi announced it will cut the price of its main insulin formulation, Lantus, in January of next year. Just outstripping the others, the cuts amount to a 78% price drop for the life-saving drug used by millions of people with diabetes. In addition, Sanofi set an out-of-pocket cap of $35 a month for patients.
According to Zachary Brennan, “The three updates all take effect after the federal government lowered OOP costs to $35 per month for everyone on Medicare, and as an upcoming major change in Medicaid policy would leave these companies and potentially others on the hook for larger rebates, creating an incentive for companies to watch their price increases.”
To read more, click here.
(Source: Endpoints News, March 17th, 2023)
